Shivalik Rasayan manufactures technical-grade agrochemicals like insecticides and fungicides, while expanding into high-value active pharmaceutical ingredients (APIs) and contract development services for global drug companies.
The company possesses a narrow moat based on regulatory licenses and technical expertise in organophosphorus chemistry. While they are a leading producer of Dimethoate and Malathion, the lack of durable pricing power is evident in the declining net margins and EPS despite revenue growth, suggesting a commodity-like competitive environment.
Management has aggressively reinvested in capacity expansion, specifically the Dahej-II and Dahej-III facilities, and backward integration. However, the EPS CAGR of -7.1% over a period of 13.3% revenue growth suggests that recent capital deployment has yet to yield incremental bottom-line value for shareholders.
The company's aggressive capital expenditure into the Dahej facilities became a classic 'commodity trap' where massive reinvestment failed to generate incremental earnings. Despite growing the top line, the business suffered from a 'profitless prosperity' as negative EPS growth persisted. The combination of weak pricing power in organophosphorus chemistry and a dismal cash conversion ratio of 0.07 meant that while the company looked busy, it was actually incinerating capital. Eventually, the persistent compliance failures and governance lapses—ranging from improper audit committee quorums to statutory violations in CSR and POSH—eroded institutional trust, leading to a permanent rerating as the market realized the business was a capital-intensive commodity play with a management team that prioritized expansion over shareholder returns.
RichFakir rates Shivalik Rasayan Ltd's business quality as mediocre — 45/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Shivalik Rasayan Ltd is trading about 94% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shivalik Rasayan Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shivalik Rasayan Ltd's fair value is about ₹155 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →